Clinical Trial: A Study in Participants With Non-cirrhotic NASH With Fibrosis
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Study Type: INTERVENTIONAL
Official Title: A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 (Mitiperstat) in Participants With Non-cirrhotic Non-alcoholic Steatoh
Brief Summary:
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial.Participants will be in the trial for up to 24 weeks, including a screening period lasting up to 8 weeks, a 12-week treatment period, and a 4-week safety follow-up periodParticipants are not expected to directly benefit from treatment during this trial.Participants will help researchers learn more about and how to develop AZD4831 to treat NASH.
Read more